Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from March 26, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on June 24, 2026 — +28.7% at the close.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$35.50 – $37.20Entry zone — fair-value band

$36.83Published — price the day we called it

$40.88Target — the price the thesis aimed for

$47.79Peak — highest point inside the window, not a realized return

$47.41Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 21 days.

At window close

+28.7%

realized, from the publication price to the last close inside the window

Peak gain

+29.8%

peak, from the publication price — not a realized return

S&P 500, same window

+14%

SPY over the identical days, dividend-adjusted

Window close

$47.41

last close inside the window, ended June 24, 2026

Peak price

$47.79

peak on May 11, 2026 — not a realized return

Days to target

The thesis — published March 26, 2026

Predicted growth

+11%

over the measurement window

Target price

$40.88

the price the thesis aimed for

Entry zone

$35.50 – $37.20

the fair-value band we waited for

Price at publication

$36.83

published March 26, 2026

Confidence

68%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Novo Nordisk still runs a strong business in diabetes and obesity, but recent negative news and a downgrade have pushed sentiment lower. Shares have dropped well below their recent trend, creating a situation where a rebound is possible if the stock settles down. Confidence is cautious until the downgrade impact lessens and the price shows clearer signs of repair.

Primary drivers

The diabetes and obesity business remains a lasting strength
The downgrade made the stock more beaten down lately
Shares traded noticeably below the recent trend after the pullback
A steadier mood in the market would lift rebound chances

How it played out

NVO: target reached in 21 days

Lyra published NVO at $36.83 with an expected 11% rebound to $40.88. The thesis pointed to the strength of its diabetes and obesity business, a recent downgrade, shares trading below their recent trend, and the prospect of steadier market sentiment.

The price reached the target in 21 days. It later peaked at $47.79 on May 11, a 29.8% gain, and ended the window at $47.41. The thesis played out and exceeded its published target.

What happened during the window

On March 27, 2026, Novo Nordisk announced US approval of Awiqli for adults with type 2 diabetes. On May 6, 2026, the company reported its first-quarter results and raised its adjusted sales and operating profit guidance.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals